PIK3C2B is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2B status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3C2B is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].